Internal R&D Versus In-licensing Complements or Substitutes
暂无分享,去创建一个
Marco Ceccagnoli | Mattew Higgins | Vincenzo Palermo | M. Ceccagnoli | Vincenzo Palermo | Mattew Higgins
[1] Robin C. Sickles,et al. The CES-Translog: Specification and Estimation of a New Cost Function , 1984 .
[2] Avi Goldfarb,et al. Understanding the Inputs into Innovation: Do Cities Substitute for Internal Firm Resources? , 2007, SSRN Electronic Journal.
[3] M. Ceccagnoli,et al. Enhancing Research Productivity through the Market for Technology , 2008 .
[4] N. Gallini. Deterrence by Market Sharing: A Strategic Incentive for Licensing , 1984 .
[5] Ignacio Fernández-de-Lucio,et al. Does external knowledge sourcing matter for innovation? Evidence from the Spanish manufacturing industry , 2009 .
[6] Reinhilde Veugelers,et al. In Search of Complementarity in Innovation Strategy: Internal R&D and External Knowledge Acquisition , 2006, Manag. Sci..
[7] P. Danzon,et al. Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.
[8] A. Arora,et al. The changing technology of technological change: general and abstract knowledge and the division of , 1994 .
[9] Jiann-Chyuan Wang,et al. External technology acquisition and firm performance: A longitudinal study , 2008 .
[10] A. Arora. Contracting for tacit knowledge: the provision of technical services in technology licensing contracts , 1996 .
[11] Jaider Vega Jurado,et al. Does external knowledge sourcing matter for innovation? Evidence from the Spanish manufacturing industry , 2009 .
[12] Jack A. Nickerson,et al. Strategic Management of R&D Pipelines with Cospecialized Investments and Technology Markets , 2007, Manag. Sci..
[13] J. Marshall. Open Innovation: The New Imperative for Creating and Profiting from Technology , 2004 .
[14] A. Arora,et al. Markets for Technology: The Economics of Innovation and Corporate Strategy , 2004 .
[15] J. Fagerberg,et al. The Oxford handbook of innovation , 2006 .
[16] Jonathan Ireland. Mergers and acquisitions in the pharmaceutical and biotech industries , 1998 .
[17] Andrea Fosfuri,et al. The Penguin Has Entered the Building: The Commercialization of Open Source Software Products , 2008, Organ. Sci..
[18] A. Gambardella. Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s * , 1992 .
[19] A. Arora,et al. Licensing the market for technology , 2003 .
[20] Matthew J. Higgins,et al. The outsourcing of R&D through acquisitions in the pharmaceutical industry , 2006 .
[21] D. Teece. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .
[22] A. Arora,et al. Markets for Technology: The Economics of Innovation and Corporate Strategy , 2002 .
[23] Nancy Gallini,et al. The Economics of Patents: Lessons from Recent U.S. Patent Reform , 2002 .
[24] Toby E. Stuart,et al. Interorganizational Endorsements and the Performance of Entrepreneurial Ventures , 1999 .
[25] A. Arora,et al. Ideas for rent: an overview of markets for technology , 2010 .
[26] Mcdp Mathieu Weggeman,et al. Determinants of the Level of Knowledge Application: A Knowledge‐Based and Information‐Processing Perspective* , 2005 .
[27] E. Helpman. General purpose technologies and economic growth , 1998 .
[28] Ashish Arora,et al. Patent Protection, Complementary Assets, and Firms' Incentives for Technology Licensing , 2004, Manag. Sci..
[29] Daniel A. Levinthal,et al. Innovation and Learning: The Two Faces of R&D , 1989 .
[30] A. Salter,et al. Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms , 2006 .
[31] Marco Ceccagnoli,et al. Productivity and the Role of Complementary Assets in Firms’ Demand for Technology Innovations , 2009 .
[32] Lloyd A. Jobe,et al. Balancing vertical integration and strategic outsourcing: effects on product portfolio, product success, and firm performance , 2006 .
[33] Andrea Shepard. Licensing to Enhance Demand for New Technologies , 1987 .
[34] G. Pisano. The R&D Boundaries of the Firm: An Empirical Analysis , 1990 .
[35] Franco Malerba,et al. Sectoral Systems: How and Why Innovation Differs across Sectors , 2006 .
[36] Julian Lowe,et al. R&D and technology purchase through licence agreements: complementary strategies and complementary assets , 1998 .
[37] Ilan Guedj. Ownership vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D , 2005 .
[38] Daron Acemoglu,et al. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry , 2003 .
[39] Massimo Riccaboni,et al. The Nature and the Extent of the Market for Technology in Biopharmaceuticals , 2004 .
[40] J. Gans,et al. Incumbency and R&D Incentives: Licensing the Gale of Creative Destruction , 1999 .
[41] F. Rothaermel,et al. Old technology meets new technology: complementarities, similarities, and alliance formation , 2008 .
[42] Mary Tripsas. Unraveling The Process Of Creative Destruction: Complementary Assets And Incumbent Survival In The Typesetter Industry , 1997 .
[43] R. Veugelers,et al. COMPLEMENTARITY BETWEEN TECHNOLOGY MAKE AND BUY IN INNOVATION STRATEGIES : EVIDENCE FROM BELGIAN MANUFACTURING FIRMS , 1998 .
[44] Sean Nicholson,et al. Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality , 2002 .
[45] H. Grabowski. Patents, Innovation and Access to New Pharmaceuticals , 2002 .
[46] Zvi Griliches,et al. Issues in Assessing the Contribution of Research and Development to Productivity Growth , 1979 .
[47] Frank T. Rothaermel,et al. Leveraging internal and external experience: exploration, exploitation, and R&D project performance , 2010 .
[48] Maurizio Zollo,et al. Deliberate Learning and the Evolution of Dynamic Capabilities , 2002 .
[49] T. J. Allen,et al. Organizational structure, information technology, and R&D productivity , 2018, IEEE Transactions on Engineering Management.
[50] F. Rothaermel. Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .
[51] A. Jaffe. Technological Opportunity and Spillovers of R&D: Evidence from Firms&Apos; Patents, Profits and Market Value , 1986 .
[52] J. Hicks. Marginal Productivity and the Principle of Variation , 1932 .
[53] I. Cockburn,et al. Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery , 2003 .
[54] A. Arora,et al. COMPLEMENTARITY AND EXTERNAL LINKAGES: THE STRATEGIES OF THE LARGE FIRMS IN BIOTECHNOLOGY* , 1990 .
[55] Ashish Arora,et al. A Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug Development , 2009, Manag. Sci..
[56] Bronwyn H. Hall,et al. Industrial Research During the 1980s: Did the Rate of Return Fall? , 1993 .
[57] Gary P. Pisano,et al. R&D Performance, Collaborative Arrangements and the Market for Know-How: A Test of the "Lemons" Hypothesis in Biotechnology , 1997 .